These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32931563)

  • 21. Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection.
    Jamieson TR; Poutou J; Marius R; He X; Rezaei R; Azad T; Ilkow CS
    J Vis Exp; 2021 Jun; (172):. PubMed ID: 34152313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
    Valcourt EJ; Manguiat K; Robinson A; Chen JC; Dimitrova K; Philipson C; Lamoureux L; McLachlan E; Schiffman Z; Drebot MA; Wood H
    Diagn Microbiol Infect Dis; 2021 Apr; 99(4):115294. PubMed ID: 33387896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission.
    Kim YI; Kim SM; Park SJ; Kim EH; Yu KM; Chang JH; Kim EJ; Casel MAB; Rollon R; Jang SG; Um J; Song MS; Jeong HW; Kim EG; Kim Y; Kim SY; Park JS; Park MS; Kwon GY; Yeo SG; Lee SA; Choi YJ; Jung JU; Choi YK
    Emerg Microbes Infect; 2021 Dec; 10(1):152-160. PubMed ID: 33407005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aptamer BC 007's Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies.
    Haberland A; Krylova O; Nikolenko H; Göttel P; Dallmann A; Müller J; Weisshoff H
    Viruses; 2021 May; 13(5):. PubMed ID: 34069827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection.
    Bladh O; Greilert-Norin N; Havervall S; Marking U; Aguilera K; Alm JJ; Blom K; Åberg M; Klingström J; Thålin C
    N Engl J Med; 2023 Oct; 389(17):1626-1628. PubMed ID: 37888924
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluation of an ELISA for SARS-CoV-2 antibody testing: clinical performances and correlation with plaque reduction neutralization titer.
    Padoan A; Bonfante F; Sciacovelli L; Cosma C; Basso D; Plebani M
    Clin Chem Lab Med; 2020 Oct; 58(11):e247-e249. PubMed ID: 32772001
    [No Abstract]   [Full Text] [Related]  

  • 27. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.
    Wajnberg A; Amanat F; Firpo A; Altman DR; Bailey MJ; Mansour M; McMahon M; Meade P; Mendu DR; Muellers K; Stadlbauer D; Stone K; Strohmeier S; Simon V; Aberg J; Reich DL; Krammer F; Cordon-Cardo C
    Science; 2020 Dec; 370(6521):1227-1230. PubMed ID: 33115920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients.
    Flehmig B; Schindler M; Ruetalo N; Businger R; Bayer M; Haage A; Kirchner T; Klingel K; Normann A; Pridzun L; Tougianidou D; Ranke MB
    Viruses; 2020 Nov; 12(12):. PubMed ID: 33260809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discordance between Serum Neutralizing Antibody Titers and the Recovery from COVID-19.
    Kalkan Yazıcı M; Koç MM; Çetin NS; Karaaslan E; Okay G; Durdu B; Sümbül B; Doymaz MZ
    J Immunol; 2020 Nov; 205(10):2719-2725. PubMed ID: 32978281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Durability of Viral Neutralization in Asymptomatic Coronavirus Disease 2019 for at Least 60 Days.
    Haymond A; Damluji AA; Narayanan A; Mueller C; Reeder A; Alem F; Maxwell GL; Petricoin EF; Liotta L; deFilippi CR
    J Infect Dis; 2021 May; 223(10):1677-1680. PubMed ID: 33718952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
    Jeong H; Choi YM; Seo H; Kim BJ
    Front Immunol; 2021; 12():637654. PubMed ID: 33732258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test.
    Meschi S; Colavita F; Bordi L; Matusali G; Lapa D; Amendola A; Vairo F; Ippolito G; Capobianchi MR; Castilletti C;
    J Clin Virol; 2020 Aug; 129():104539. PubMed ID: 32679298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera.
    Perera RAPM; Ko R; Tsang OTY; Hui DSC; Kwan MYM; Brackman CJ; To EMW; Yen HL; Leung K; Cheng SMS; Chan KH; Chan KCK; Li KC; Saif L; Barrs VR; Wu JT; Sit THC; Poon LLM; Peiris M
    J Clin Microbiol; 2021 Jan; 59(2):. PubMed ID: 33139421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection.
    Choe PG; Kang CK; Suh HJ; Jung J; Song KH; Bang JH; Kim ES; Kim HB; Park SW; Kim NJ; Park WB; Oh MD
    Emerg Infect Dis; 2021 Jan; 27(1):327-9. PubMed ID: 33050983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralizing SARS-CoV-2.
    Poeschla E
    Elife; 2020 Dec; 9():. PubMed ID: 33320086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the Anti-SARS-CoV-2 Surrogate Neutralization Assays by TECOmedical and DiaPROPH-Med with Samples from Vaccinated and Infected Individuals.
    Münsterkötter L; Hollstein MM; Hahn A; Kröger A; Schnelle M; Erpenbeck L; Groß U; Frickmann H; Zautner AE
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel immunofluorescent test system for SARS-CoV-2 detection in infected cells.
    Rak A; Matyushenko V; Prokopenko P; Kostromitina A; Polyakov D; Sokolov A; Rudenko L; Isakova-Sivak I
    PLoS One; 2024; 19(5):e0304534. PubMed ID: 38820303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibility of livestock to SARS-CoV-2 infection.
    Bosco-Lauth AM; Walker A; Guilbert L; Porter S; Hartwig A; McVicker E; Bielefeldt-Ohmann H; Bowen RA
    Emerg Microbes Infect; 2021 Dec; 10(1):2199-2201. PubMed ID: 34749583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.